PASG - Passage BIO, Inc.
8.4
0.280 3.333%
Share volume: 66,082
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.17%
PREVIOUS CLOSE
CHG
CHG%
$8.12
0.28
0.03%
Fundamental analysis
27%
Profitability
36%
Dept financing
16%
Liquidity
50%
Performance
15%
Performance
5 Days
5.00%
1 Month
-5.62%
3 Months
-15.32%
6 Months
21.39%
1 Year
1,958.82%
2 Year
479.31%
Key data
Stock price
$8.40
DAY RANGE
$7.77 - $8.58
52 WEEK RANGE
$0.26 - $20.00
52 WEEK CHANGE
$1,958.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
Company detail
CEO: William Chou
Region: US
Website: passagebio.com
Employees: 130
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: passagebio.com
Employees: 130
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysososomal acid beta-galactosidase for infantile GM1. The company also develops PBML04 for the treatment of metachromatic leukodystrophy.
Recent news